TherapeuticsMD Appoints Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-Chief Executive Officers
September 12 2022 - 6:50AM
Business Wire
- Robust Strategic Alternatives Process
Continues -
TherapeuticsMD, Inc. (NASDAQ: TXMD), (“TherapeuticsMD” or the
“Company”) an innovative, leading women’s healthcare company,
announced today the appointment of Dr. Brian Bernick and Mr. Mark
Glickman as the Company’s Interim Co-Chief Executive Officers and
Co-Principal Executive Officers. Dr. Bernick and Mr. Glickman
succeed Mr. Hugh O’Dowd as the Company’s Chief Executive
Officer.
Prior to this appointment, Dr. Bernick, the Company’s
co-founder, served as Chief Scientific and Medical Officer, and Mr.
Glickman served as Chief Business Officer.
The Company also announced that the Board of Directors appointed
The Honorable Tommy Thompson, who served as the Company’s Chairman
of the Board since 2012, as the Executive Chairman of the
Board.
“I have had the privilege of working with Dr. Bernick, our
founder and innovator of our products, for many years. His
dedication to improving women’s health is unparalleled, and the
Board of Directors looks forward to his leadership as we continue
to thoroughly evaluate strategic alternatives,” said the Hon. Tommy
Thompson, Executive Chairman of the Board. “Mr. Glickman brings 30
years of leadership and deep pharmaceutical knowledge. We believe
that the appointments of Dr. Bernick and Mr. Glickman will enhance
our ongoing and robust strategic review process. The Board and I
look forward to working with them both to deliver the highest
possible value to shareholders,” concluded Thompson.
About TherapeuticsMD, Inc.
TherapeuticsMD, Inc. is an innovative, leading healthcare
company, focused on developing and commercializing novel products
exclusively for women. TherapeuticsMD’s products are designed to
address the unique changes and challenges women experience through
the various stages of their lives with a therapeutic focus in
family planning, reproductive health, and menopause management.
TherapeuticsMD is committed to advancing the health of women and
championing awareness of their healthcare issues. To learn more
about TherapeuticsMD, please visit https://www.therapeuticsmd.com/
or follow us on Twitter: @TherapeuticsMD and on Facebook:
TherapeuticsMD.
Cautionary Notes Regarding Forward Looking Statements
This press release contains forward-looking statements.
Forward-looking statements may include, but are not limited to,
statements relating to the Company’s objectives, plans and
strategies as well as statements, other than historical facts, that
address activities, events or developments that the company
intends, expects, projects, believes or anticipates will or may
occur in the future. These statements are often characterized by
terminology such as “believes,” “hopes,” “may,” “anticipates,”
“should,” “intends,” “plans,” “will,” “expects,” “estimates,”
“projects,” “positioned,” “strategy” and similar expressions and
are based on assumptions and assessments made in light of
management’s experience and perception of historical trends,
current conditions, expected future developments and other factors
believed to be appropriate. Forward-looking statements in this
press release are made as of the date of this press release, and
the Company undertakes no duty to update or revise any such
statements, whether as a result of new information, future events
or otherwise. Forward-looking statements are not guarantees of
future performance and are subject to risks and uncertainties, many
of which are outside of the Company’s control. Important factors
that could cause actual results, developments and business
decisions to differ materially from forward-looking statements are
described in the sections titled “Risk Factors” in the Company’s
filings with the Securities and Exchange Commission, including its
most recent Annual Report on Form 10-K and Quarterly Reports on
Form 10-Q, as well as Current Reports on Form 8-K, and include the
following: whether the company will be able to refinance the
indebtedness under its term loan facility, and, if not, whether the
Company will be able to continue as a going concern; whether the
Company will be able to raise capital to fund its operations; the
effects of management transitions; the effects of the COVID-19
pandemic; the Company’s ability to maintain or increase sales of
its products; the Company’s ability to develop and commercialize
IMVEXXY®, ANNOVERA®, and BIJUVA® and obtain additional financing
necessary therefor; the effects of supply chain issues on the
supply of the Company’s products; the potential of adverse side
effects or other safety risks that could adversely affect the
commercialization of the company’s current or future approved
products or preclude the approval of the Company’s future drug
candidates; the Company’s ability to protect its intellectual
property; the length, cost and uncertain results of future clinical
trials; the Company’s reliance on third parties to conduct its
manufacturing, research and development and clinical trials; the
ability of the Company’s licensees to commercialize and distribute
the Company’s products; the ability of the Company’s marketing
contractors to market ANNOVERA; the availability of reimbursement
from government authorities and health insurance companies for the
Company’s products; the impact of product liability lawsuits; the
influence of extensive and costly government regulation; the
volatility of the trading price of the Company’s common stock.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220912005338/en/
Lisa M. Wilson In-Site Communications, Inc. 212-452-2793
lwilson@insitecony.com
TherapeuticsMD 561-961-1900 IR@TherapeuticsMD.com
TherapeuticsMD (NASDAQ:TXMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
TherapeuticsMD (NASDAQ:TXMD)
Historical Stock Chart
From Sep 2023 to Sep 2024